PROMOTioN

PROMOTioN
Name	PROMOTioN
Type	Research consortium
Founded	2015
Location	Europe
Focus	Cardio-oncology; ventricular arrhythmia; sudden cardiac death
Key people	Martin Borggrefe; Christian Wolpert; Hein Heidbuchel

PROMOTioN

PROMOTioN was a multinational European research consortium focused on improving risk stratification and prevention of sudden cardiac death through novel diagnostic and therapeutic strategies, combining electrophysiology, imaging, genomics, and device technologies. The initiative brought together clinical centers, academic institutions, industry partners, and regulatory stakeholders to perform prospective studies, multicenter trials, and translational research across the European Union, linking expertise from landmark projects and institutions in Germany, Belgium, Italy, United Kingdom, and Netherlands. PROMOTioN emphasized collaboration with registries, guideline bodies, and technology developers to accelerate implementation into practice.

Background and Objectives

PROMOTioN was launched to address gaps identified after major studies such as MADIT-II, SCD-HeFT, DINAMIT, IRIS and guideline deliberations by European Society of Cardiology, American College of Cardiology, Heart Rhythm Society and national bodies. Its objectives included improving prediction of ventricular arrhythmia beyond standard measures like left ventricular ejection fraction used in MUSTT, integrating biomarkers validated in cohorts such as Framingham Heart Study, ARIC, and UK Biobank, and evaluating device therapy innovations from manufacturers like Medtronic, Abbott Laboratories, Boston Scientific, and Biotronik. The consortium aimed to align outcomes with regulatory frameworks from European Medicines Agency and reimbursement criteria influenced by National Institute for Health and Care Excellence and Health Technology Assessment networks.

Consortium Partners and Governance

The consortium assembled university hospitals linked to Charité – Universitätsmedizin Berlin, University College London Hospitals, KU Leuven, Università di Pavia, Universitätsklinikum Schleswig-Holstein, and research centers associated with Max Planck Society and INSERM. Industry participation included device and software firms including MicroPort, GE Healthcare, and biotech companies that collaborated with academic groups tied to Imperial College London, Oxford University Hospitals, and Karolinska Institutet. Governance structures invoked models similar to consortia like Innovative Medicines Initiative and Horizon 2020 projects, with steering committees reflecting representatives from European Commission funding units, ethics committees from institutional review boards at participating centers, and data safety monitoring boards modeled after those in trials led by Stefan Blaschke and Ewa Jankowska. Intellectual property and data-sharing agreements drew on precedents from collaborations with World Health Organization affiliated networks and legal frameworks influenced by General Data Protection Regulation deliberations.

Study Design and Methods

PROMOTioN employed prospective, multicenter observational cohorts and randomized substudy designs echoing methodologies from PROSE-ICD, EUROASPIRE, and BIG-Heart initiatives. Methods combined advanced electrophysiological mapping influenced by techniques from EnSite and CARTO platforms, cardiac magnetic resonance protocols developed alongside Society for Cardiovascular Magnetic Resonance, and genomic analyses leveraging biobanks such as deCODE genetics and Estonian Biobank. Statistical approaches referenced standards set by consortia like RE-LY and ORBIT-AF, using core labs at centers with expertise from Mayo Clinic, Cleveland Clinic, and Mount Sinai Hospital. Data harmonization used common data models akin to those from Observational Health Data Sciences and Informatics and quality control procedures similar to multicenter stroke trials coordinated by European Stroke Organisation.

Key Findings and Outcomes

PROMOTioN reported that multimodal risk models combining electrocardiographic indices, scar quantification by cardiac MRI, circulating biomarkers studied in cohorts like BIOSTAT-CHF, and polygenic risk scores improved discrimination for ventricular arrhythmia over left ventricular ejection fraction alone, echoing advances reported by groups at Johns Hopkins Hospital and Brigham and Women's Hospital. Device-based monitoring strategies reduced inappropriate therapies when integrated with machine-learning algorithms developed in collaboration with teams from ETH Zurich and Imperial College London, paralleling innovations from MIT and Stanford University. Substudies showed cost-effectiveness outcomes comparable to analyses by World Bank health economists and health technology assessments by IQWiG and Haute Autorité de Santé.

Clinical and Regulatory Impact

Findings informed guideline discussions within European Society of Cardiology working groups and influenced policy consultations with European Commission expert panels and national regulators such as Medicines and Healthcare products Regulatory Agency and Federal Institute for Drugs and Medical Devices. Results were used by device manufacturers like Abbott Laboratories and Medtronic to refine remote monitoring algorithms and by clinical networks including ESC Heart Failure Association to propose updates to implantation criteria, echoing the translation pathways used by trials like DANISH and COMPANION.

Publications and Dissemination

PROMOTioN disseminated results through high-impact journals and conferences such as The Lancet, European Heart Journal, Circulation, Heart Rhythm, ESC Congress, American Heart Association Scientific Sessions, and specialist meetings hosted by Heart Failure Association and HRS Scientific Sessions. Collaborators contributed to consensus documents and white papers alongside societies including European Association of Cardiovascular Imaging and International Society for Heart and Lung Transplantation, and data were presented in workshops at institutions like University of Oxford and Harvard Medical School.

Legacy and Future Directions

PROMOTioN's legacy includes data resources and methodological frameworks adopted by subsequent initiatives such as HARMONY Alliance style consortia, translational projects at Wellcome Trust-funded centers, and ongoing registries managed by networks like EuroHeart. Future directions emphasize integration with precision medicine efforts at European Reference Networks, expanded partnerships with artificial intelligence groups at DeepMind and OpenAI affiliates, and alignment with Horizon Europe funding mechanisms to sustain implementation into clinical pathways influenced by WHO cardiovascular action plans.

Category:Cardiology research consortia